DENTSPLY SIRONA (NASDAQ:XRAY) Raised to “Hold” at BMO Capital Markets

DENTSPLY SIRONA (NASDAQ:XRAY) was upgraded by analysts at BMO Capital Markets to a “hold” rating in a research report issued on Wednesday,Zacks.com reports.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Citigroup initiated coverage on shares of DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target for the company. Mizuho cut their price target on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. UBS Group reduced their price objective on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Finally, Barclays decreased their price objective on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating for the company in a research note on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $13.42.

DENTSPLY SIRONA Price Performance

NASDAQ:XRAY opened at $11.89 on Wednesday. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -3.77, a PEG ratio of 1.40 and a beta of 0.89. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. The business has a 50 day simple moving average of $10.59 and a 200-day simple moving average of $11.67. DENTSPLY SIRONA has a 1 year low of $9.40 and a 1 year high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The company had revenue of $880.00 million for the quarter, compared to the consensus estimate of $841.80 million. During the same period in the prior year, the firm posted $0.43 EPS. The business’s revenue for the quarter was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts forecast that DENTSPLY SIRONA will post 1.42 EPS for the current year.

Insider Transactions at DENTSPLY SIRONA

In related news, Director Brian T. Gladden bought 9,985 shares of the stock in a transaction dated Monday, June 15th. The stock was purchased at an average cost of $10.02 per share, with a total value of $100,049.70. Following the completion of the purchase, the director owned 61,849 shares of the company’s stock, valued at $619,726.98. This trade represents a 19.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael J. Barber purchased 15,175 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the acquisition, the director owned 55,943 shares of the company’s stock, valued at approximately $552,716.84. The trade was a 37.22% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 35,160 shares of company stock worth $351,179. 0.46% of the stock is currently owned by insiders.

Hedge Funds Weigh In On DENTSPLY SIRONA

Institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of DENTSPLY SIRONA in the first quarter valued at approximately $26,000. Goldman Sachs Group Inc. increased its holdings in DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after purchasing an additional 2,172,343 shares during the period. Empowered Funds LLC raised its position in DENTSPLY SIRONA by 8.8% during the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in DENTSPLY SIRONA by 7.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after purchasing an additional 41,579 shares in the last quarter. Finally, Focus Partners Wealth lifted its holdings in shares of DENTSPLY SIRONA by 59.1% in the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock worth $376,000 after buying an additional 9,355 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.